About Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company developing oncology-focused small molecule therapies targeting RNA-modifying proteins (RMPs) in the field of epitranscriptomics. The company leverages a robust chemical biology platform to identify and exploit cancer-specific intracellular dependencies across multiple tumor types. Its lead clinical programs include ATX-295 (KIF18A inhibitor) and ATX-559 (DHX9 inhibitor), aimed at patients with significant unmet medical need.
Company details
Funding
Total raised
$178M
Last stage
Series C
Investors
Founders
Robert A. Copeland
Co-Founder and President of Accent Therapeutics; previously served as Chief Scientific Officer at the company.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.